Teva Pharma present late-breaking present data presented highlighting primary and secondary outcome measure results from chronic and episodic migraine Phase III clinical trials
- Co presented new data evaluating fremanezumab, an investigational treatment for the prevention of migraine.
- Data presented across two platform presentations and five late-breaking abstracts featured detailed, positive efficacy results from pivotal Phase III HALO studies of fremanezumab in chronic and episodic migraine, as well as data from patient-reported outcomes tools in the chronic migraine trial.
- Across the Phase III HALO studies in chronic and episodic migraine, fremanezumab achieved statistically significant and clinically meaningful results for all 25 primary and secondary analyses in both monthly and quarterly dosing regimens. In the chronic migraine study, endpoint analyses presented at IHC include:
- Significant reduction in the number of monthly headache days of at least moderate severity during the 12-week period after 1st dose for both dosing regimens
- Statistically significant reduction in the number of monthly migraine days during the 12-week period after the 1st dose, for both dosing regimens versus placebo and during the 4-week period after 1st dose, for both dosing regimens
- Improvement in Migraine-Specific Quality of Life scores for both dosing regimens
- Improvement in overall health status as measured by the EuroQol 5-dimension 5 response level questionnaire for both dosing regimens
- Significant reduction in the weekly number of headache days of at least moderate severity at week 1 versus placebo (-0.5 days)
Teva Pharma appoints Kare Schultz as President/CEO
- Co announced that its Board of Directors has named Kre Schultz to become the Company's President and Chief Executive Officer.
- Schultz will succeed Dr. Yitzhak Peterburg, who will continue to serve as Interim Chief Executive Officer until Schultz joins the Company.
- He most recently served as the President and Chief Executive Officer of H. Lundbeck A/S (HLUYY)
- The leadership announcement represents the successful completion of the global search process to identify the best leader for the Company and was executed by the Teva Board
No comments:
Post a Comment